A randomised trial of primary tamoxifen versus mastectomy plus adjuvant tamoxifen in fit elderly women with invasive breast carcinoma of high oestrogen receptor content: long-term results at 20 years of follow-up

Johnston, S. J.; Kenny, F. S.; Syed, B. M.; Robertson, J. F. R.; Pinder, S. E.; Winterbottom, L.; Ellis, I. O.; Blamey, R. W.; Cheung, K. L.

doi:10.1093/annonc/mdr630

All Outputs (29)

Detection in blood of autoantibodies to tumour antigens as a case-finding method in lung cancer using the EarlyCDT®-Lung Test (ECLS): study protocol for a randomized controlled trial (2017)
Journal Article
Sullivan, F., Farmer, E., Mair, F. S., Treweek, S., Kendrick, D., Jackson, C., …Schembri, S. (2017). Detection in blood of autoantibodies to tumour antigens as a case-finding method in lung cancer using the EarlyCDT®-Lung Test (ECLS): study protocol for a randomized controlled trial. BMC Cancer, 17(1), https://doi.org/10.1186/s12885-017-3175-y

Background: Lung cancer is the most common cause of cancer related death worldwide. The majority of cases are detected at a late stage when prognosis is poor. The EarlyCDT®-Lung Test detects autoantibodies to abnormal cell surface proteins in the ear... Read More about Detection in blood of autoantibodies to tumour antigens as a case-finding method in lung cancer using the EarlyCDT®-Lung Test (ECLS): study protocol for a randomized controlled trial.

Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial (2016)
Journal Article
Robertson, J. F., Bondarenko, I. M., Trishkina, E., Dvorkin, M., Panasci, L., Manikhas, A., …Ellis, M. J. (2016). Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. Lancet, 388(10063), 2997-3005. https://doi.org/10.1016/S0140-6736%2816%2932389-3

Background Aromatase inhibitors are a standard of care for hormone receptor-positive locally advanced or metastatic breast cancer. We investigated whether the selective oestrogen receptor degrader fulvestrant could improve progression-free surviva... Read More about Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial.

Breast conservation in ductal carcinoma in situ (DCIS): what defines optimal margins? (2016)
Journal Article
Toss, M. S., Pinder, S. E., Green, A. R., Thomas, J., Morgan, D. A., Robertson, J. F., …Rakha, E. A. (2017). Breast conservation in ductal carcinoma in situ (DCIS): what defines optimal margins?. Histopathology, 70(5), 681-692. https://doi.org/10.1111/his.13116

The introduction of mammographic screening has resulted in a rise in the detection rate of ductal carcinoma in situ (DCIS), currently accounting for one‐fifth of screen‐detected breast cancers. Although 60–70% of DCIS are treated with breast‐conservi... Read More about Breast conservation in ductal carcinoma in situ (DCIS): what defines optimal margins?.

Human blood autoantibodies in the detection of colorectal cancer (2016)
Journal Article
Negm, O. H., Hamed, M. R., Schoen, R. E., Whelan, R. L., Steele, R. J., Scholefield, J., …Sewell, H. F. (2016). Human blood autoantibodies in the detection of colorectal cancer. PLoS ONE, 11(7), 1-14. https://doi.org/10.1371/journal.pone.0156971

Colorectal cancer (CRC) is the second most common malignancy in the western world. Early detection and diagnosis of all cancer types is vital to improved prognosis by enabling early treatment when tumours should be both resectable and curable. Sera f... Read More about Human blood autoantibodies in the detection of colorectal cancer.

Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST Study (2015)
Journal Article
Robertson, J., Ellis, M., Llombart-Cussac, A., Feltl, D., Dewar, J., Jasiówka, M., …Rukazenkov, Y. (2015). Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST Study. Journal of Clinical Oncology, 33(32), 3781-3787. https://doi.org/10.1200/JCO.2015.61.5831

Purpose To compare overall survival (OS) for fulvestrant 500 mg versus anastrozole as first-line endocrine therapy for advanced breast cancer. Patients and Methods The Fulvestrant First-Line Study Comparing Endocrine Treatments (FIRST) was a... Read More about Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST Study.

Biological effects of fulvestrant on estrogen receptor positive human breast cancer: Short, medium and long-term effects based on sequential biopsies. (2015)
Journal Article
Agrawal, A., Robertson, J. F., Cheung, K. L., Gutteridge, E., Ellis, I. O., Nicholson, R. I., & Gee, J. M. (2015). Biological effects of fulvestrant on estrogen receptor positive human breast cancer: Short, medium and long-term effects based on sequential biopsies. International Journal of Cancer, 138(1), 146-159. https://doi.org/10.1002/ijc.29682

Serum autoantibody measurement for the detection of hepatocellular carcinoma (2014)
Journal Article
Middleton, C. H., Irving, W., Robertson, J. F., Murray, A., Parsy-Kowalska, C. B., Macdonald, I. K., …Thomson, B. J. (2014). Serum autoantibody measurement for the detection of hepatocellular carcinoma. PLoS ONE, 9(8), 1-9. https://doi.org/10.1371/journal.pone.0103867

Background: Individuals with liver disease, and especially those with Hepatitis B or C, are at an increased risk of developing hepatocellular carcinoma (HCC) which is the third most common cause of cancer-related death worldwide. Inadequate screening... Read More about Serum autoantibody measurement for the detection of hepatocellular carcinoma.

Audit of the autoantibody test, EarlyCDT®-Lung, in 1600 patients: An evaluation of its performance in routine clinical practice (2013)
Journal Article
Jett, J. R., Peek, L. J., Fredericks, L., Jewell, W., Pingleton, W. W., & ROBERTSON, J. (2014). Audit of the autoantibody test, EarlyCDT®-Lung, in 1600 patients: An evaluation of its performance in routine clinical practice. Lung Cancer, 83(1), 51-55. https://doi.org/10.1016/j.lungcan.2013.10.008

Objectives EarlyCDT®-Lung may enhance detection of early stage lung cancer by aiding physicians in assessing high-risk patients through measurement of biological markers (i.e., autoantibodies). The test's performance characteristics in routine clini... Read More about Audit of the autoantibody test, EarlyCDT®-Lung, in 1600 patients: An evaluation of its performance in routine clinical practice.

A randomised trial of primary tamoxifen versus mastectomy plus adjuvant tamoxifen in fit elderly women with invasive breast carcinoma of high oestrogen receptor content: long-term results at 20 years of follow-up (2012)
Journal Article
Johnston, S. J., Kenny, F. S., Syed, B. M., Robertson, J. F. R., Pinder, S. E., Winterbottom, L., …Cheung, K. L. (2012). A randomised trial of primary tamoxifen versus mastectomy plus adjuvant tamoxifen in fit elderly women with invasive breast carcinoma of high oestrogen receptor content: long-term results at 20 years of follow-up. Annals of Oncology, 23(9), 2296-2300. https://doi.org/10.1093/annonc/mdr630

Background Long-term analysis of a randomised trial in Nottingham comparing tamoxifen versus surgery as initial treatment demonstrated that in oestrogen receptor (ER)-unselected cases, surgery achieved better local control, with no difference in ove... Read More about A randomised trial of primary tamoxifen versus mastectomy plus adjuvant tamoxifen in fit elderly women with invasive breast carcinoma of high oestrogen receptor content: long-term results at 20 years of follow-up.